Beigene

Beigene Liabilities

The The Liabilities of Beigene (6160.HK) as of Oct 31, 2026 is 30.08 B USD. In the previous year, The Liabilities was 20.29 B USD — a change of 48.29% (higher).

Liabilities

30.08 BUSD

YoY

48.29%

Last updated:

In 2025, Beigene's total liabilities amounted to 30.08 B USD, a 48.29% difference from the 20.29 B USD total liabilities in the previous year.

The Beigene Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
3.89 B USD
Jan 1, 2019
4.97 B USD
Jan 1, 2020
2.00 B USD
Jan 1, 2021
18.83 B USD
Jan 1, 2022
15.64 B USD
Jan 1, 2023
17.77 B USD
Jan 1, 2024
20.29 B USD
Jan 1, 2025
30.08 B USD
The Beigene Liabilities history
YEARLiabilitiesYoY
30.08 BUSD+48.29%
20.29 BUSD+14.14%
17.77 BUSD+13.63%
15.64 BUSD-16.94%
18.83 BUSD+841.02%
2.00 BUSD-59.72%
4.97 BUSD+27.80%
3.89 BUSD+36.93%
2.84 BUSD-10.74%
3.18 BUSD+247.55%
914.99 MUSD+319.22%
218.26 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Beigene's Liabilities

Beigene's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Beigene's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Beigene's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Beigene's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Beigene’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Beigene stock

The Liabilities of Beigene is 30.08 B USD in 2025.

The Liabilities of Beigene changed from 20.29 B USD to 30.08 B USD, representing a 48.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Beigene since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Beigene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Beigene

All Key Metrics — Beigene